SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Pictured: 3D illustration of antibody-drug conjugates with their toxic payloads
Pheon Raises $120M in Series B to Advance ADCs for Hard-to-Treat Cancers
London-based Pheon Therapeutics will use the funds to push its three lead antibody-drug conjugate candidates through clinical proof-of-target studies.
May 22, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Pfizer's signage at its world headquarters in New York
Policy
Wyden Targets Pfizer in Ongoing Pharma Tax Investigation in Letter to CEO
As part of an ongoing Senate investigation into pharma companies’ tax rates, Sen. Ron Wyden (D-Ore.) has asked Pfizer CEO Albert Bourla to explain irregularities in its reported revenues, losses and taxes paid.
May 22, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: J&J's office in Madrid, Spain
Drug Development
J&J Positions Tremfya as Stelara Successor with Strong Head-to-Head Data
Johnson & Johnson on Tuesday released Phase II/III results showing its monoclonal antibody Tremfya is better than its blockbuster Stelara in terms of endoscopic outcomes in Crohn’s disease.
May 22, 2024
 · 
2 min read
 · 
Tristan Manalac
AstraZeneca's sign on its office in California
Business
AstraZeneca Sets $80B Revenue Target, Goal of 20 New Drugs by 2030
AstraZeneca on Tuesday laid out an ambitious plan to boost growth in its existing oncology, biopharma and rare disease portfolios, as well as launch 20 new medicines before the end of the decade.
May 21, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Doctor holding up a lung x-ray
Drug Development
Sanofi, Regeneron Post Strong Phase III COPD Data for Dupixent as FDA Decision Looms
Late-stage results from the NOTUS trial showed Sanofi and Regeneron’s Dupixent lowered moderate to severe chronic obstructive pulmonary disease exacerbations by 34% and led to significantly better lung function.
May 21, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Man carrying a box of his office items after being laid off
Policy
BIO Axes 30 Staff in Realignment as Congress Advances BIOSECURE Act
Following its recent about-face on the BIOSECURE Act, designed to combat China’s influence in the biopharma industry, lobbying group Biotechnology Innovation Organization in a realignment is laying off 30 employees.
May 21, 2024
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its office in Maryland
FDA
FDA Greenlights Two Interchangeable Biosimilars to Regeneron’s Eylea
The regulator on Monday approved two interchangeable biosimilars to Regeneron’s Eylea, providing additional competition for the pharma’s blockbuster as key patent protections are set to expire.
May 21, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: A graphic showing figures on opposing coin stacks
Business
9 Top Biopharma CEO-to-Employee Pay Gaps
Despite weathering a difficult year, biopharma continues to see massive pay gaps between CEOs and their median employees, with top executives often earning hundreds of times more.
May 21, 2024
 · 
9 min read
 · 
Tristan Manalac
Pictured: AstraZeneca's building in Shanghai, China
Drug Delivery
AstraZeneca to Build $1.5B ADC Manufacturing Plant in Singapore
To support its growing antibody-drug conjugate portfolio, AstraZeneca on Monday said it is investing $1.5 billion in a Singapore production site that will include all steps of the ADC manufacturing process.
May 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Sign at the European Patent Office's headquarters in Germany
Drug Development
Moderna Gets Win in COVID-19 Patent Dispute with Pfizer, BioNTech
The European Patent Office last week upheld one of Moderna’s key patents, handing the biotech an important victory in its protracted COVID-19 vaccine battle with Pfizer and BioNTech.
May 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Sign above the entrance to a U.S. courthouse
Policy
AstraZeneca to Pay Pfizer $107.5M in Damages in Tagrisso Patent Tussle
Pfizer’s Wyeth unit notched a legal victory over AstraZeneca on Friday as a federal jury found the British-Swedish company violated two key patents in developing and marketing its lung cancer drug Tagrisso.
May 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Man prepares his GLP-1 receptor agonist injection
Drug Development
GLP-1 Receptor Agonist Market to Reach $125B by 2033: GlobalData
While Eli Lilly and Novo Nordisk currently dominate the GLP-1 receptor agonist space, there are more than 50 candidates in clinical development for obesity and type 2 diabetes, according to analytics firm GlobalData.
May 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Amgen's office in Tampa, Florida
FDA
Amgen Wins FDA Approval for Difficult-to-Treat Lung Cancer
Bolstered by promising response data from its Phase II study, Amgen announced Thursday it got the FDA’s green light for its first-in-class bi-specific T-cell engager Imdelltra for extensive-stage small lung cancer.
May 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: GSK laboratories in Dresden, Germany
GSK to Sell Remaining Stake in Haleon, Looks to Raise $1.52B
GSK said Thursday it plans to divest its remaining 4.2% stake in the consumer health spinout, its fourth and final round of selling off Haleon shares worth approximately $1.52 billion.
May 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Biogen’s headquarters in Massachusetts
Business
Biogen Drops Ionis-Partnered Assets in ALS, Angelman Syndrome After Early-Stage Readouts
Disappointed with Phase I/II results for two Ionis-partnered programs, one for amyotrophic lateral sclerosis and another for Angelman syndrome, Biogen has opted to not proceed with their development.
May 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More